Pharmacological and genetic perturbation establish SIRT5 as a promising target in breast cancer
Yashira L. Negrón Abril,Irma R. Fernandez,Jun Young Hong,Ying-Ling Chiang,Dennis A. Kutateladze,Qingjie Zhao,Min Yang,Jing Hu,Sushabhan Sadhukhan,Bo Li,Bin He,Brenna Remick,Jessica Jingyi Bai,James Mullmann,Fangyu Wang,Viviana Maymi,Ravi Dhawan,Johan Auwerx,Teresa Southard,Richard A. Cerione,Hening Lin,Robert S. Weiss
DOI: https://doi.org/10.1038/s41388-020-01637-w
IF: 8.756
2021-01-21
Oncogene
Abstract:SIRT5 is a member of the sirtuin family of NAD<sup>+</sup>-dependent protein lysine deacylases implicated in a variety of physiological processes. SIRT5 removes negatively charged malonyl, succinyl, and glutaryl groups from lysine residues and thereby regulates multiple enzymes involved in cellular metabolism and other biological processes. SIRT5 is overexpressed in human breast cancers and other malignancies, but little is known about the therapeutic potential of SIRT5 inhibition for treating cancer. Here we report that genetic <i>SIRT5</i> disruption in breast cancer cell lines and mouse models caused increased succinylation of IDH2 and other metabolic enzymes, increased oxidative stress, and impaired transformation and tumorigenesis. We, therefore, developed potent, selective, and cell-permeable small-molecule SIRT5 inhibitors. SIRT5 inhibition suppressed the transformed properties of cultured breast cancer cells and significantly reduced mammary tumor growth in vivo, in both genetically engineered and xenotransplant mouse models. Considering that <i>Sirt5</i> knockout mice are generally normal, with only mild phenotypes observed, these data establish SIRT5 as a promising target for treating breast cancer. The new SIRT5 inhibitors provide useful probes for future investigations of SIRT5 and an avenue for targeting SIRT5 as a therapeutic strategy.
oncology,genetics & heredity,biochemistry & molecular biology,cell biology